NATIONAL TAIWAN UNIVERSITY HOSPITAL
國立臺灣大學醫學院附設醫院
Research Team
護理部創新研發成果
智慧給藥檢核系統：胡文郁教授團隊
電話：02-23123456#263139
Email：irisuniworld@ntuh.gov.tw
易利鈎-360度旋轉伸縮掛鈎：胡文郁教授團隊／連絡人：高秀娥
電話：02-23123456#263341、0972651148
Email：kao5636@ntuh.gov.tw
運用3D列印技術導入護理教學：兩性導尿語音會陰沖洗教學模具：
康佳雯、高秀娥、郭哲安
多功能安全輪椅：林美蓉、高秀娥、林乃華、李鴻春、吳佳燕
姚明醫師
CD19嵌合抗原受體T細胞療法於血液惡性腫瘤之應用
CD19-targeted CAR T-cell therapeutics for hematologic malignancies
2017年8月美國食品藥物管理局（FDA）核准全球首個細胞免疫療法-CAR-T，用以治療「瀰漫性大B細胞淋巴瘤」與「兒童B細胞急性淋巴性白血病」，此開創性癌症治療將全球醫學進展推進下一里程碑，為難治與復發型的血液性癌症患者帶來一線生機，並且開啟再生醫療的新紀元。有鑑於細胞免疫療法-CAR-T是全球癌症治療趨勢，臺大醫院全力籌措GTP實驗室及引進國際細胞治療品質管理系統，設立「臨床細胞治療中心」，規劃細胞治療專區以提供專業安全細胞治療環境。本中心執行本院所有細胞治療的相關業務，以健全臨床端細胞治療流程管控及病人安全並提升細胞治療動態管理及病例追蹤，率先成為我國首家可正式提供臨床使用CAR-T之醫學中心。
陳偉勵主治醫師
電紡紗生醫材料-PBG對角膜神經系統修復的應用
The Application of Electrospun Biomaterial-PBG on the Corneal Nerve Regeneration
Until now, there have been no effective therapies for neurological disorders. As for peripheral nerve diseases, although not causing death directly, severely impact patients' health and quality of life. Our team has developed a biomedical material suitable for neural repair called the “Electrospun Biomedical Scaffold - PBG.” PBG exhibits good plasticity, biocompatibility, and degradability. It can sustained-release the excitatory neurotransmitter “glutamate” which promotes neural growth and induces the differentiation of iPSCs into retinal ganglion cells. Furthermore, it has shown the ability to repair damaged trigeminal nerves in in vitro experiments. In animal transplantation experiments, the PBG scaffold was demonstrated to directly promote the regeneration of damaged corneal nerves. The “Electrospun Biomedical Scaffold - PBG” holds great potential to become an “Electrospun Scaffold Artificial Cornea” that aids in the repair of damaged corneal nerves.
胡務亮教授
AADC缺乏症基因治療
Gene therapy for AADC deficiency
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare genetic neurological disorder caused by autosomal recessive inherited pathogenic mutants of the DDC gene, which prevents the conversion of L-3,4-dihydroxyphenylalanine (L-DOPA) into dopamine (DA) that leads to decreased availability of serotonin and dopamine in the presynaptic and synaptic cleft, as well as a deficiency of catecholamines. AADC deficiency results in movement disorders including hypokinesia, dystonia, and oculogyric crisis, along with behavioral problems, autonomic dysfunction, and developmental delay. The rationale for intraputaminal AADC gene therapy is to deliver a functional copy of the human DDC gene (hAADC) with a recombinant adeno-associated virus type 2 (AAV2) vector directly to striatal regions impacted by the disease, which subsequently leads to increased conversion of levodopa to DA in targeted striatal neuronal cell bodies. Patients received AAV2-hAADC infused bilaterally into the putamen. The procedure and treatment were well tolerated. An increase in dopamine production could be demonstrated by positron emission tomography and neurotransmitter analysis.